Cue Biopharma (NASDAQ:CUE) Posts Quarterly Earnings Results, Misses Estimates By $2.50 EPS

Cue Biopharma (NASDAQ:CUE – Get Free Report) issued its earnings results on Monday. The company reported ($4.74) earnings per share for the quarter, missing the consensus estimate of ($2.24) by ($2.50), FiscalAI reports. The company had revenue of $0.13 million for the quarter, compared to analyst estimates of $1.03 million. Cue Biopharma had a negative return on equity of 620.06% and a negative net margin of 435.83%.

Cue Biopharma Trading Down 12.5%

CUE opened at $14.10 on Tuesday. Cue Biopharma has a one year low of $4.97 and a one year high of $45.50. The business’s 50 day moving average price is $23.67 and its 200 day moving average price is $105.57.

Insider Buying and Selling

In other Cue Biopharma news, CEO Shao-Lee Lin sold 11,087 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $27.55, for a total transaction of $305,446.85. Following the completion of the sale, the chief executive officer owned 694,908 shares of the company’s stock, valued at $19,144,715.40. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sumita Ray sold 1,844 shares of Cue Biopharma stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.05, for a total value of $51,724.20. Following the completion of the sale, the insider owned 116,701 shares in the company, valued at $3,273,463.05. This represents a 1.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 14,075 shares of company stock worth $389,260. Company insiders own 14.56% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on CUE. Zacks Research raised Cue Biopharma to a “hold” rating in a report on Monday, September 21st. Wall Street Zen lowered Cue Biopharma from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 26th. Weiss Ratings lowered Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. Finally, B. Riley Financial initiated coverage on Cue Biopharma in a report on Friday, September 18th. They issued a “buy” rating and a $83.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Cue Biopharma currently has a consensus rating of “Hold” and a consensus target price of $83.00.

Read Our Latest Stock Analysis on CUE

About Cue Biopharma

(Get Free Report)

Cue Biopharma, Inc. is a biotechnology company developing biologic medicines designed to selectively engage and modulate T cells. Its Immuno-STAT platform is intended to direct immune activity toward disease-specific targets, with potential applications in cancer and autoimmune disorders. The company’s research has included cancer candidates such as CUE-101, designed to target HPV16-positive cancers, and CUE-102, developed to target cancers expressing the WT1 protein. Cue Biopharma has also pursued programs intended to influence immune responses in autoimmune disease.

Read More

Earnings History for Cue Biopharma (NASDAQ:CUE)

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.